ANI Pharmaceuticals Inc (NASDAQ:ANIP) has earned an average rating of “Hold” from the seven research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $72.67.
Several analysts have issued reports on the company. BidaskClub downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, February 22nd. ValuEngine downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th. Canaccord Genuity set a $75.00 price objective on ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, December 9th. TheStreet downgraded ANI Pharmaceuticals from a “b” rating to a “c+” rating in a report on Tuesday, February 20th. Finally, Zacks Investment Research downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd.
ANI Pharmaceuticals (NASDAQ:ANIP) traded down $2.29 during midday trading on Friday, reaching $59.75. The company’s stock had a trading volume of 165,868 shares, compared to its average volume of 168,226. The company has a current ratio of 3.36, a quick ratio of 2.39 and a debt-to-equity ratio of 1.13. The firm has a market cap of $695.67, a P/E ratio of 56.37 and a beta of 2.75. ANI Pharmaceuticals has a 12-month low of $42.23 and a 12-month high of $74.70.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.06. The firm had revenue of $47.30 million for the quarter, compared to the consensus estimate of $52.55 million. ANI Pharmaceuticals had a positive return on equity of 23.41% and a negative net margin of 0.61%. The business’s revenue for the quarter was up 23.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.84 EPS. research analysts forecast that ANI Pharmaceuticals will post 5.17 earnings per share for the current fiscal year.
In other news, Director Tracy Marshbanks sold 64,221 shares of the company’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $63.03, for a total value of $4,047,849.63. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Robert W. Schrepfer sold 28,652 shares of the company’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $61.66, for a total value of $1,766,682.32. Following the completion of the transaction, the senior vice president now owns 41,590 shares in the company, valued at approximately $2,564,439.40. The disclosure for this sale can be found here. Insiders sold a total of 180,405 shares of company stock worth $11,257,715 in the last quarter. 31.80% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of ANIP. Bank of Montreal Can increased its holdings in shares of ANI Pharmaceuticals by 681.8% in the 4th quarter. Bank of Montreal Can now owns 2,408 shares of the specialty pharmaceutical company’s stock valued at $156,000 after purchasing an additional 2,100 shares during the period. SG Americas Securities LLC acquired a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at about $197,000. Millennium Management LLC acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at about $210,000. Violich Capital Management Inc. bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $217,000. Finally, Driehaus Capital Management LLC bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at approximately $220,000. Institutional investors own 55.95% of the company’s stock.
WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/ani-pharmaceuticals-inc-anip-receives-average-rating-of-hold-from-analysts.html.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.